BIAL
DEAD

Serial Number

85583401

Owner

BIAL - PORTELA & CA, S.A.

Attorney

James L. Bikoff

Filing Date

Mar 29, 2012

Add to watchlist:

No watchlists yet
View on USPTO

BIAL Trademark

Serial Number: 85583401 • Registration: 4490162

BIAL is a trademark filed by BIAL - PORTELA & CA, S.A. on March 29, 2012. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

BIAL - PORTELA & CA, S.A. (34 trademarks)

A AV. DA SIDERURGIA NACIONAL
S. MAMEDE DO CORONADO 4745-457 , PT

Entity Type: 03

Trademark Details

Filing Date

March 29, 2012

Registration Date

March 4, 2014

Published for Opposition

March 19, 2013

Cancellation Date

October 9, 2020

Goods & Services

Pharmaceutical preparations for the treatment of cardiovascular diseases, urological disorders, gastrointestinal disorders, allergies, diabetes, hypertension, erectile dysfunction, sexual dysfunction, stroke, cancer, migraines, obesity and respiratory diseases, fungal disorders; pharmaceutical preparations, namely, anti-inflammatory analgesics; pharmaceutical preparations, namely, cholesterol reducers, smoking cessation preparations, tissue and skin repair preparations; pharmaceutical preparations, namely, decongestants and anti-histamines; pharmaceutical preparations for the treatment of pains, cough, fever, angina, otorhinolaryngological diseases, gastric and liver illnesses, heart illnesses, arterial and venous illnesses, rheumatic illnesses; anaesthetics; analgesics; frostbite salve for pharmaceutical purposes; hemorrhoid treatment preparations; pharmaceutical preparations for the treatment of headaches; medicines for alleviating constipation; contraceptive preparations; radiological contrast substances for medical purposes; diagnostic preparations for medical purposes; pharmaceuticals for the treatment of pain, fever, angina, otorhinolaryngological diseases, gastric and liver illnesses, heart illnesses, arterial and venous illnesses, rheumatic illnesses; pharmaceutical preparations for the treatment of diabetes, cancer; pharmaceutical preparations for the prevention and treatment of cancer, carcinomas and sarcomas; pharmaceutical preparations for the prevention and treatment of tumours of any description; pharmaceutical preparations, namely, platelet stimulating factors; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, bipolar disorder, neuropathic pain, migraine, generalized anxiety disorder, social phobia, diabetic neuropathies, panic disorder, postoperative pain, back pain, fibromyalgia, and postherpetic neuralgia, post-traumatic stress disorder, Parkinson's disease, Alzheimers; pharmaceutical preparations for the treatment of psychiatric diseases, namely, schizophrenia, anxiety disorders, mood disorders, cognitive disorders, depression, mania; pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the respiratory system; pharmaceutical preparations for treatment of gout, namely, broncho-dilators and anti-asthmatic preparations; pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the peripheral nervous system, cardiovascular system, gastro-intestinal system; prescription pharmaceutical preparations and substances for use in pain control, anaesthesia, oncology; prescription pharmaceutical preparations and substances for the treatment and prevention of diabetes; pharmaceutical preparations and substances, namely, antibiotics, antivirals, antidiabetic preparations, nondepolarizing skeletal neuromuscular blocking agents, hemostatic agents, expectorants, anti-leukemia agents, anti-arrhythmics, dermatologicals and vasopressors; pharmaceutical preparations and substances for the treatment of cancer, HIV, obesity, and respiratory and urologic disorders and diseases; pharmaceutical preparations and substances for the treatment of acute ischemic stroke and traumatic brain injury (TBI); cerebral vasodilators; pharmaceutical preparations for the treatment of smooth muscle disorders, headaches, wrinkles, hyperhydrosis, sports injuries, namely, injured or torn skin, muscle, ligaments or bone, tremors, namely, spasmodic smooth, striated or cardiac muscles, and pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; pharmaceutical preparations for the treatment of muscle dystonias, nerve disorders, and spasmodic striated, smooth or cardiac muscles; pharmaceutical preparations for the treatment of cerebral palsy; pharmaceutical preparations, namely, muscle relaxants and anti-emetics, xanthine oxidase inhibitors; pharmaceutical preparations, namely, scabicides, anti-malarials

Pharmaceutical, medical and biological research and development in the field of human therapeutics; conducting of pre-clinical and clinical test research in the pharmaceutical and medical fields; scientific research and development in the field of human medicine

Filing History

CANCELLED SEC. 8 (6-YR)
Oct 9, 2020 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 4, 2019 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 15, 2015 TCCA
REGISTERED-PRINCIPAL REGISTER
Mar 4, 2014 R.PR
PAPER RECEIVED
Jan 28, 2014 MAIL
TTAB RELEASE CASE TO TRADEMARKS
Jan 28, 2014 TMBN
OPPOSITION TERMINATED NO. 999999
Jan 28, 2014 OP.T
OPPOSITION DISMISSED NO. 999999
Jan 28, 2014 OP.D
OPPOSITION INSTITUTED NO. 999999
Jul 16, 2013 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Apr 16, 2013 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 19, 2013 NPUB
PUBLISHED FOR OPPOSITION
Mar 19, 2013 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 27, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 11, 2013 PREV
ASSIGNED TO LIE
Feb 11, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 11, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 11, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 11, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 11, 2012 GNRN
NON-FINAL ACTION E-MAILED
Jul 11, 2012 GNRT
NON-FINAL ACTION WRITTEN
Jul 11, 2012 CNRT
ASSIGNED TO EXAMINER
Jul 10, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2012 NWOS
NEW APPLICATION ENTERED
Apr 2, 2012 NWAP